San Diego, California, USA, October 16, 2026
Neurocrine Biosciences has presented new real-world evidence showing how classic congenital adrenal hyperplasia (CAH) can affect patients differently throughout their lives, from infancy and childhood to adolescence and adulthood. The findings, announced on October 16, 2026, will be presented at the Endocrine Nurses Society Annual Symposium 2026 in Phoenix, Arizona. The analysis used decades of de-identified electronic medical records from the CAHtalog® patient registry, developed by Neurocrine Biosciences in partnership with the CARES Foundation. By connecting medical histories into longitudinal patient journeys, researchers examined how clinical complications, treatment requirements, monitoring, and everyday challenges change over time. The findings highlight the importance of lifelong disease management, individualized care, and coordination among healthcare professionals to support people living with this rare genetic endocrine disorder.
Real-World Data Reveals Changing Patient Needs
The analysis examined electronic medical records from 10 adults with classic CAH, including four males and six females, covering more than 2,800 CAH-related events and over 300 patient-years of medical history. Researchers used a patient-journey mapping approach supported by large language model-assisted analysis, with the resulting journeys reviewed and validated by the study team. The records revealed that the challenges associated with CAH evolve across different life stages. During infancy, care often centers on diagnosis, treatment, managing acute illness, and preparing caregivers to administer emergency steroid doses when needed. In childhood, growth monitoring and bone-age assessments become increasingly important. During adolescence, androgen-related symptoms, puberty, hormone monitoring, and maintaining treatment routines can become more prominent. Young adulthood may introduce reproductive health needs, surgical considerations, and transitions from pediatric to adult healthcare services. In later adulthood, patients may experience a broader range of health concerns requiring additional testing, imaging, and specialist care. These observations illustrate how CAH management extends beyond hormone control to affect daily functioning, education, employment, and family life.
Ongoing Treatment and Coordinated Care Remain Essential
The findings also highlight the continuing demands of glucocorticoid treatment and hormone monitoring throughout life. Glucocorticoids help replace cortisol that the body cannot produce adequately and support the management of excess adrenal androgen production. However, treatment requirements may change during illness, injury, or other periods of physical stress, making patient and caregiver education particularly important. Records from all 10 patients documented glucocorticoid dose adjustments and stress dosing over time. The analysis also identified recurring needs related to specialist referrals, healthcare access, changes in providers, and transitions to adult endocrinology services. Neurocrine noted that treatment management often shifts from caregiver-led support during childhood toward greater self-management in adulthood. These findings suggest that proactive education, individualized monitoring, and coordinated care teams may help healthcare professionals anticipate patients’ changing needs. However, the study was descriptive and included a small number of patients; its findings are illustrative rather than estimates of how frequently particular challenges occur across the wider CAH population. Further research in larger and more diverse patient groups will be important to validate these observations and assess their implications for long-term care.
Advertisement
Source: Neurocrine Biosciences press release
